JP2010502718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502718A5 JP2010502718A5 JP2009527442A JP2009527442A JP2010502718A5 JP 2010502718 A5 JP2010502718 A5 JP 2010502718A5 JP 2009527442 A JP2009527442 A JP 2009527442A JP 2009527442 A JP2009527442 A JP 2009527442A JP 2010502718 A5 JP2010502718 A5 JP 2010502718A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liver
- ppar
- alcohol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 32
- 206010067125 Liver injury Diseases 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 21
- 210000004185 liver Anatomy 0.000 claims description 20
- 231100000753 hepatic injury Toxicity 0.000 claims description 19
- 229940126033 PPAR agonist Drugs 0.000 claims description 18
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims description 17
- 208000019423 liver disease Diseases 0.000 claims description 16
- 230000008929 regeneration Effects 0.000 claims description 16
- 238000011069 regeneration method Methods 0.000 claims description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 12
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 11
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 11
- 238000010171 animal model Methods 0.000 claims description 9
- 231100000234 hepatic damage Toxicity 0.000 claims description 9
- 230000008818 liver damage Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 238000011670 long-evans rat Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 230000005778 DNA damage Effects 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000003746 Insulin Receptor Human genes 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000003859 lipid peroxidation Effects 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84298306P | 2006-09-08 | 2006-09-08 | |
| US60/842,983 | 2006-09-08 | ||
| PCT/US2007/019610 WO2008030595A2 (en) | 2006-09-08 | 2007-09-10 | Treatment, prevention, and reversal of alcohol-induced liver disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010502718A JP2010502718A (ja) | 2010-01-28 |
| JP2010502718A5 true JP2010502718A5 (https=) | 2011-10-20 |
| JP5864077B2 JP5864077B2 (ja) | 2016-02-17 |
Family
ID=39157885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527442A Expired - Fee Related JP5864077B2 (ja) | 2006-09-08 | 2007-09-10 | アルコール誘発性肝疾患の治療、予防および回復 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9717719B2 (https=) |
| EP (1) | EP2061484B1 (https=) |
| JP (1) | JP5864077B2 (https=) |
| KR (1) | KR101922515B1 (https=) |
| AU (1) | AU2007292874B2 (https=) |
| CA (1) | CA2663115C (https=) |
| ES (1) | ES2399147T3 (https=) |
| WO (1) | WO2008030595A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007044487A1 (de) * | 2007-09-18 | 2009-04-02 | Universität Leipzig | Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe |
| JP2013194007A (ja) * | 2012-03-21 | 2013-09-30 | Cci Corp | 抗酸化ストレス剤およびその用途 |
| FR3004354A1 (fr) * | 2013-04-10 | 2014-10-17 | Alfact Innovation | Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline |
| AU2019225820A1 (en) * | 2018-02-20 | 2020-09-10 | EMULATE, Inc. | Human microphysiological cell system for liver disease conversion with prov 1-18585 and prov 2-19154 |
| US20210145774A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| CN113244225B (zh) * | 2021-06-16 | 2022-06-28 | 昆明医科大学第一附属医院 | 土槿皮乙酸在制备抗血小板药物中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2058785B (en) * | 1979-09-05 | 1983-05-25 | Glaxo Group Ltd | Phenol derivatives |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5223242A (en) | 1985-11-05 | 1993-06-29 | The General Hospital Corporation | Negatively charged specific affinity reagents |
| US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US5326770A (en) | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
| DE4311651A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
| US5482698A (en) | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
| DE4418965A1 (de) | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen |
| US5780010A (en) | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
| US5958371A (en) | 1995-06-08 | 1999-09-28 | Barnes-Jewish Hospital | Site specific binding system, nuclear imaging compositions and methods |
| US5690907A (en) | 1995-06-08 | 1997-11-25 | The Jewish Hospital Of St. Louis | Avidin-biotin conjugated emulsions as a site specific binding system |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| CA2295930C (en) | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
| US6713514B1 (en) | 1999-04-19 | 2004-03-30 | Lexicon Pharmaceuticals, Inc. | PPAR-γ agonists as agents for the treatment of type II diabetes |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| US6462046B2 (en) | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
| JP2004507455A (ja) * | 2000-04-25 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途 |
| EP1409010A4 (en) * | 2000-07-03 | 2005-06-29 | Probendo Pty Ltd | TREATMENT OF endotoxemia AND OF DISORDERS ASSOCIATED BY OF PROBIOTICS |
| IL153543A0 (en) | 2000-07-20 | 2003-07-06 | Bristol Myers Squibb Co | PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY |
| EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
| WO2002032291A2 (en) | 2000-10-19 | 2002-04-25 | The General Hospital Corporation | Imaging of enzymatic activity |
| UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
| US7371777B2 (en) * | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| US20050235143A1 (en) * | 2002-08-20 | 2005-10-20 | Koninkljke Philips Electronics N.V. | Mobile network authentication for protection stored content |
| BR0314335A (pt) | 2002-09-05 | 2005-07-26 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade |
| AU2004259000A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
| JP2007527416A (ja) | 2003-10-31 | 2007-09-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体 |
| KR100849352B1 (ko) | 2003-11-05 | 2008-07-29 | 에프. 호프만-라 로슈 아게 | Ｐｐａｒ 활성화제로서 벤조-융합된 화합물 |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| CN1946698B (zh) | 2004-04-28 | 2010-12-01 | 霍夫曼-拉罗奇有限公司 | 作为ppar活化剂的吡唑苯基衍生物 |
-
2007
- 2007-09-10 CA CA2663115A patent/CA2663115C/en not_active Expired - Fee Related
- 2007-09-10 ES ES07837941T patent/ES2399147T3/es active Active
- 2007-09-10 EP EP07837941A patent/EP2061484B1/en not_active Not-in-force
- 2007-09-10 KR KR1020097007164A patent/KR101922515B1/ko not_active Expired - Fee Related
- 2007-09-10 JP JP2009527442A patent/JP5864077B2/ja not_active Expired - Fee Related
- 2007-09-10 AU AU2007292874A patent/AU2007292874B2/en not_active Ceased
- 2007-09-10 US US12/310,832 patent/US9717719B2/en not_active Expired - Fee Related
- 2007-09-10 WO PCT/US2007/019610 patent/WO2008030595A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Becker et al. | Sex differences in drug abuse | |
| EP2538978B1 (en) | Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis | |
| RU2492858C2 (ru) | Композиции и способы профилактики и лечения зависимостей | |
| JP2010502718A5 (https=) | ||
| Campbell et al. | Sex differences in the effects of baclofen on the acquisition of intravenous cocaine self-administration in rats | |
| US20070060638A1 (en) | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist | |
| EA200870365A1 (ru) | Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ | |
| JP2003095979A (ja) | ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置 | |
| JP2007512371A5 (https=) | ||
| KR102056756B1 (ko) | 다발성 경화증의 치료를 위한 PPARγ 작용제 | |
| HRP20240319T1 (hr) | Pripravci i postupci za liječenje anemije | |
| EA200800007A1 (ru) | Фармацевтические композиции на основе нейроактивного стероида и их применение | |
| GB2465250A (en) | Dosing and monitoring patients on nitrogen-scavenging drugs | |
| IL308132A (en) | Methods of treatment of autoimmune disorders using ilt7 binding proteins | |
| JP2004537500A5 (https=) | ||
| JP2010502719A5 (https=) | ||
| BRPI0717867A2 (pt) | Redução de sobrepeso ou obesidade | |
| WO2009047562A1 (en) | Methods and compositions for the treatment of pruritus | |
| JP2001520989A (ja) | 哺乳動物における欲求を減少する方法 | |
| Semenova et al. | Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats | |
| Arima et al. | Positive effect of baclofen on body weight reduction in obese subjects: a pilot study | |
| EP2020999B1 (en) | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance | |
| WO2024040935A1 (zh) | 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用 | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| Tong et al. | Is the GLP-1 system a viable therapeutic target for weight reduction? |